Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC)

被引:54
作者
Subramanian, Janakiraman
Velcheti, Vamsidhar
Gao, Feng
Govindan, Ramaswamy
机构
[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Alvin Siteman Canc Ctr, St Louis, MO 63110 USA
关键词
non-small cell lung cancer; never-smoker; outcomes; presentation;
D O I
10.1097/JTO.0b013e318145af79
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Tobacco smoking leads to lung cancer. Approximately 10% of patients with lung cancer are life long never-smokers. There are only limited data available on the clinical characteristics and outcomes of lung cancer in never-smokers from the Western hemisphere. Methods: Demographic and survival information was collected on 254 never-smokers with a confirmed pathologic diagnosis of non-small cell lung cancer (NSCLC) by reviewing their medical records and the Social Security database. Results: The study population consisted of 182 (71.6%) women and 72 (28.3%) men. The median age was 70 years (range: 31-91 years). Adenocarcinoma was the most common histology accounting for 60.8% of all patients, followed by NSCLC not otherwise specified (14.4%), bronchoalveolar carcinoma (13.6%), squamous cell carcinoma (8.8%), and large-cell type (2.4%), Majority of patients presented with stage III or IV disease (62.5%). We compared survival between never-smokers and smokers with NSCLC matched for gender, histology, tumor stage, and years of diagnosis. No significant difference in 5-year survival was seen between never-smokers (27.2%) and smokers with NSCLC (31.3%; p = 0.73). Conclusions: Two thirds of patients with lung cancer who report no history of tobacco smoking are women. In the matched case-control analysis, we report no significant survival difference between lung cancer in never-smokers and those with history of tobacco smoking and lung cancer.
引用
收藏
页码:827 / 830
页数:4
相关论文
共 36 条
[1]  
Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO
[2]  
2-H
[3]   Epidemiology and prevention of lung cancer in nonsmokers [J].
Brownson, RC ;
Alavanja, MCR ;
Caporaso, N ;
Simoes, EJ ;
Chang, JC .
EPIDEMIOLOGIC REVIEWS, 1998, 20 (02) :218-236
[4]  
Dibble R, 2005, J CLIN ONCOL, V23, p683S
[5]   ENVIRONMENTAL TOBACCO-SMOKE AND LUNG-CANCER IN NONSMOKING WOMEN - A MULTICENTER STUDY [J].
FONTHAM, ETH ;
CORREA, P ;
REYNOLDS, P ;
WUWILLIAMS, A ;
BUFFLER, PA ;
GREENBERG, RS ;
CHEN, VW ;
ALTERMAN, T ;
BOYD, P ;
AUSTIN, DF ;
LIFF, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (22) :1752-1759
[6]   Mutations and addiction to EGFR:: the Achilles 'heal' of lung cancers? [J].
Gazdar, AF ;
Shigematsu, H ;
Herz, J ;
Minna, JD .
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (10) :481-486
[7]  
GAZDAR AF, 2005, AM SOC CLIN ONCOLOGY, P619
[8]  
GOODGAME B, 2006, J CLIN ONCOL S, V18, P7205
[9]   Hospital based survey of lung cancer in Turkey, a developing country, where smoking is highly prevalent [J].
Gursel, G ;
Levent, E ;
Ozturk, C ;
Karalezli, A .
LUNG CANCER, 1998, 21 (02) :127-132
[10]   TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke:: lessons from the IARC TP53 mutation database [J].
Hainaut, P ;
Olivier, M ;
Pfeifer, GP .
MUTAGENESIS, 2001, 16 (06) :551-553